ClinicalTrials.gg
CompletedNCT00427895Updated Nov 15, 2021Results posted

Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults

A Phase 3 interventional study of 13-valent pneumococcal conjugate vaccine (13vPnC) and 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) in Pneumococcal Infections, sponsored by Pfizer. Completed at 26 sites in United States. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-11-15.

Sponsored by Pfizer · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,141
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections — none open to participants now, 1 under way, none of them phase 3. 13-valent pneumococcal vaccine · Pneumococcal Infections.

Enrollment
2nd of 44
2,141 · median 328
Started
2007
with 5 others
Phase 3
19 of 44
none open now
Registered
2nd of 44
by date
Lead sponsor
16 of 44
Pfizer

Among the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections, this one is the 2nd largest by enrollment, is one of 6 that started in 2007, is one of 19 in phase 3, and was the 2nd registered.

Pneumococcal Infections

298 studies on the registry are indexed under Pneumococcal Infections; 25 are open to participants now.

Browse Pneumococcal Infections studies →

Open to participants now

None of the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections is open now. The open studies under Pneumococcal Infections, anywhere →

About 13-valent pneumococcal vaccine

13-valent pneumococcal vaccine: first FDA approval 2010 (Prevnar 13). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections as a file.
02

Study summary

This study will assess the safety, tolerability and immune response of 13-valent pneumococcal conjugate vaccine (13vPnC) compared with 23-valent Pneumococcal Polysaccharide Vaccine (23vPS). Although the study started with only 1 population, amendments to the original protocol will now reflect three participant populations. Three age cohorts will be enrolled. The first cohort (age 60-64) will be blinded. Cohort 2 (age 50-59) and cohort 3 (age 18-49) are open label. Subjects in cohorts 1 and 2 will receive 2 vaccinations 3-4 years apart. Subjects in cohort 3 will receive 1 vaccination. All participants should be naïve of 23vPS. Comparisons of immune responses from the different cohorts will be done.

03

Conditions studied

  • Pneumococcal Infections

Keywords

  • Vaccine
  • Pneumococcal Infections Prevention and Control
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • First Cohort: Healthy Male and female adults 60 to 64 years of age at time of enrollment.
  • Second Cohort: Healthy Male and female adults 50 to 59 years of age at time of enrollment.
  • Third Cohort: Healthy Male and female adults 18 to 49 years of age at time of enrollment.

Exclusion criteria

Exclusion Criteria:

  • Previous immunization with any licensed or experimental pneumococcal vaccine.
  • Serious chronic disorders including , severe (COPD) requiring supplemental oxygen, end stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder which in the investigator's opinion precludes the subject from participating in the study.
  • Known or suspected impairment of immunological function.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
2,141 participants (actual)

Study arms

  • Experimental
    13vPnC Cohort 1, Vaccination 1

    Participants aged 60-64 years were given a 0.5 mL dose administered on day 1.

    Biological: 13-valent pneumococcal conjugate vaccine (13vPnC)

  • Active comparator
    23vPS Cohort 1, Vaccination 1

    Participants aged 60-64 years were given a 0.5 mL dose administered on day 1.

    Biological: 23-valent Pneumococcal Polysaccharide Vaccine (23vPS)

  • Experimental
    13vPnC Cohort 2, Vaccination 1

    Participants aged 50-59 years given a 0.5 mL dose administered on day 1.

    Biological: 13-valent pneumococcal conjugate vaccine (13vPnC)

  • Experimental
    13vPnC Cohort 3, Vaccination 1

    Participants aged 18-49 years given a 0.5 mL dose administered on day 1.

    Biological: 13-valent pneumococcal conjugate vaccine (13vPnC)

  • Experimental
    13vPnC Cohort 1, Vaccination 2

    Participants aged 60-64 years who received 13vPnC at vaccination 1 receive a 0.5 mL dose of 13vPnC administered 3-4 years after dose 1.

    Biological: 13-valent pneumococcal conjugate vaccine (13vPnC)

  • Active comparator
    23vPS Cohort 1, Vaccination 2

    Participants aged 60-64 years who received 23vPS at vaccination 1 receive a 0.5 mL dose of 23vPS administered 3-4 years after dose 1.

    Biological: 23-valent Pneumococcal Polysaccharide Vaccine (23vPS)

  • Experimental
    13vPnC Cohort 2, Vaccination 2

    Participants aged 50-59 years who received 13vPnC at vaccination 1 receive a 0.5 mL dose of 13vPnC administered 3-4 years after dose 1.

    Biological: 13-valent pneumococcal conjugate vaccine (13vPnC)

Interventions

06

What researchers measure

Primary outcomes

  1. Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) 1 Month After Vaccination 1

    Serotype-specific OPA GMTs for the 13 pneumococcal common serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of all the participants using microcolony OPA (mcOPA) assay. CIs for GMT are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.

    Time frame: One month after vaccination 1

  2. Percentage of Participants Achieving At Least a 4-fold Rise in OPA Titer for Serotype 6A 1 Month After Vaccination 1 in Cohort 1

    For serotype 6A the percentage of participants achieving at least a 4-fold rise on the serotype-specific antibody titer from pre-vaccination to 1 month post-vaccination was computed along with exact, 2-sided 95% confidence interval for the proportion.

    Time frame: One month after vaccination 1

  3. Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) 1 Month After Vaccination for 12 Common Serotypes in 13vPnC/23vPS Group Relative to 23vPS Group and 23vPS/23vPS Group

    Serotype-specific OPA GMTs for the 12 pneumococcal common serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of all the participants using mcOPA assay. CIs for GMT are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.

    Time frame: One month after vaccination 1 and One month after vaccination 2/Year 3 to 4

Secondary outcomes

  1. Percentage of Participants Achieving OPA Titers With at Least Lower Limit of Quantification (LLOQ) 1 Month After Vaccination 1

    Percentage of participants achieving OPA GMTs with at least LLOQ for 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) determined in blood samples of all participants using mcOPA assay. Exact 2-sided CI based on observed proportion of participants. LLOQ for each serotype: 1=1:18, 3=1:12, 4=1:21, 5=1:29, 6A=1:37, 6B=1:43, 7F=1:210, 9V=1:345, 14=1:35, 18C=1:31, 19A=1:18, 19F=1:48, 23F=1:13.

    Time frame: One month after vaccination 1

  2. Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Fold Rises (GMFRs) for the 13 Serotypes From Prevaccination 1 to 1 Month After Vaccination 2 in Cohort 1 and Cohort 2

    Geometric mean fold rises (GMFRs) for the 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from prevaccination to 1 month postvaccination were computed using the logarithmically transformed assay results. CI for the GMFRs are back transformations of a CI based on the Student t distribution for the logarithmically transformed assay results.

    Time frame: Prevaccination 1 to 1 month after vaccination 2/Year 3 to 4

  3. Serotype-specific Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentration (GMC) for 12 Common Serotypes in 13vPnC/23vPS Group Relative to 23vPS and 23vPS/23vPS Groups in Cohort 1; and in 13vPnC/13vPnC Group in Cohort 2, 1 Month After Vaccination

    Antibody geometric mean concentration (GMC) as measured by microgram/milliliter (mcg/mL) for 12 common pneumococcal serotypes (1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) are presented. GMC and corresponding 2-sided 95% confidence intervals (CI) were evaluated. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw.

    Time frame: One month after vaccination 1 and One month after vaccination 2/Year 3 to 4

Other outcomes

  1. Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination 2 (Year 3 to 4) in Cohort 1 and Cohort 2

    Local reactions reported using an electronic diary. Redness and Swelling scaled as Any (redness present or swelling present); Mild (2.5 to 5.0 cm; Moderate (5.1 to 10.0 cm); Severe (\>10 cm). Pain scaled as Any (pain present); Mild (awareness of pain; easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating); Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move arm above head; able to move arm above shoulder); Severe (unable to move arm above shoulder).

    Time frame: Within 14 days after vaccination 2

  2. Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination 2 (Year 3 to 4) in Cohort 1 and Cohort 2

    Systemic events reported using an electronic diary. Systemic events are any fever \>=38 degrees C, fatigue, headache, chills, rash, vomiting, decreased appetite, new generalized muscle pain, aggravated generalized muscle pain , new generalized joint pain), and aggravated generalized joint pain.

    Time frame: Within 14 days after vaccination 2

  3. Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination 1

    Local reactions reported using an electronic diary. Redness and Swelling scaled as Any (redness present or swelling present); Mild (2.5 to 5.0 centimeters \[cm\]; Moderate (5.1 to 10.0 cm); Severe (\>10 cm). Pain scaled as Any (pain present); Mild (awareness of pain; easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating); Limitation of arm movement scaled as Any (limitation \[lim\] present); Mild (some limitation); Moderate (unable to move arm above head; able to move arm above shoulder); Severe (unable to move arm above shoulder).

    Time frame: Within 14 days after vaccination 1

  4. Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination 1

    Systemic events reported using an electronic diary. Systemic events are any fever greater than or equal to (\>=) 38 degrees Celsius \[C\], fatigue, headache, chills, rash, vomiting, decreased appetite, new generalized (gen) muscle pain, aggravated generalized muscle pain , new generalized joint pain), and aggravated generalized joint pain. All reports of fever \>40 degrees C in 13vPnC and 23vPS for Cohort 1 were confirmed as data entry errors.

    Time frame: Within 14 days after vaccination 1

07

Results

Posted Sep 5, 2012

Participant flow

Between 6-Month Follow-up - Year 1
Participant flow — Between 6-Month Follow-up - Year 1
Milestone13vPnC, Cohort 123vPS, Cohort 113vPnC, Cohort 213vPnC, Cohort 313vPnC/13vPnC, Cohort 113vPnC/23vPS, Cohort 123vPS/23vPS, Cohort 113vPnC/13vPnC, Cohort 2
Started4114113928540000
Completed4114113925020000
Not completed0003520000
Withdrew: Did not enter 1-year blood draw0003520000
Vax 2/Year 3 to 4
Participant flow — Vax 2/Year 3 to 4
Milestone13vPnC, Cohort 123vPS, Cohort 113vPnC, Cohort 213vPnC, Cohort 313vPnC/13vPnC, Cohort 113vPnC/23vPS, Cohort 123vPS/23vPS, Cohort 113vPnC/13vPnC, Cohort 2
Started0000108108189214
Completed0000107108189212
Not completed00001002
Withdrew: Lost to follow-up00000001
Withdrew: Protocol violation00000001
Withdrew: Failed to return00001000
Vax 1 Baseline/6-Month Follow-up
Participant flow — Vax 1 Baseline/6-Month Follow-up
Milestone13vPnC, Cohort 123vPS, Cohort 113vPnC, Cohort 213vPnC, Cohort 313vPnC/13vPnC, Cohort 113vPnC/23vPS, Cohort 123vPS/23vPS, Cohort 113vPnC/13vPnC, Cohort 2
Started4184174069000000
Vaccinated4174144048990000
Completed4114113928540000
Not completed7614460000
Withdrew: Lost to follow-up014320000
Withdrew: Protocol violation40320000
Withdrew: Physician decision11000000
Withdrew: Withdrawal by subject11470000
Withdrew: Failed to return00020000
Withdrew: Randomized, not vaccinated13210000
Withdrew: Other00120000
Vax 1/Year 1 Follow-up
Participant flow — Vax 1/Year 1 Follow-up
Milestone13vPnC, Cohort 123vPS, Cohort 113vPnC, Cohort 213vPnC, Cohort 313vPnC/13vPnC, Cohort 113vPnC/23vPS, Cohort 123vPS/23vPS, Cohort 113vPnC/13vPnC, Cohort 2
Started4114113925020000
Completed4043963734690000
Not completed71519330000
Withdrew: Lost to follow-up052210000
Withdrew: Protocol violation33010000
Withdrew: Withdrawal by subject36540000
Withdrew: Adverse event01000000
Withdrew: Death10000000
Withdrew: Failed to return001250000
Withdrew: Other00020000
Between Year 1 - Vax 2/Year 3 to 4
Participant flow — Between Year 1 - Vax 2/Year 3 to 4
Milestone13vPnC, Cohort 123vPS, Cohort 113vPnC, Cohort 213vPnC, Cohort 313vPnC/13vPnC, Cohort 113vPnC/23vPS, Cohort 123vPS/23vPS, Cohort 113vPnC/13vPnC, Cohort 2
Started4043963734690000
Completed21618921400000
Not completed1882071594690000
Withdrew: Did not consent to receive vax 21882071594690000

Outcome measures

Other pre-specifiedPercentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination 2 (Year 3 to 4) in Cohort 1 and Cohort 2

Local reactions reported using an electronic diary. Redness and Swelling scaled as Any (redness present or swelling present); Mild (2.5 to 5.0 cm; Moderate (5.1 to 10.0 cm); Severe (\>10 cm). Pain scaled as Any (pain present); Mild (awareness of pain; easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating); Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move arm above head; able to move arm above shoulder); Severe (unable to move arm above shoulder).

Time frame:
Within 14 days after vaccination 2
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination 2 (Year 3 to 4) in Cohort 1 and Cohort 2
Percentage of participants13vPnC/13vPnC, Cohort 123vPS/23vPS, Cohort 113vPnC/23vPS, Cohort 113vPnC/13vPnC, Cohort 2
Redness: Any20.0 (10.0 to 33.7)35.8 (26.8 to 45.5)27.5 (15.9 to 41.7)21.4 (13.2 to 31.7)
Redness: Mild20.0 (10.0 to 33.7)27.7 (19.3 to 37.5)22.4 (11.8 to 36.6)18.1 (10.5 to 28.0)
Redness: Moderate6.3 (1.3 to 17.2)18.7 (11.3 to 28.2)11.4 (3.8 to 24.6)5.3 (1.5 to 13.1)
Redness: Severe0.0 (0.0 to 7.5)10.6 (5.0 to 19.2)2.4 (0.1 to 12.6)1.4 (0.0 to 7.4)
Swelling: Any24.5 (13.8 to 38.3)35.6 (26.4 to 45.6)20.4 (10.2 to 34.3)22.6 (14.2 to 33.0)
Swelling: Mild21.2 (11.1 to 34.7)20.9 (13.1 to 30.7)18.8 (8.9 to 32.6)21.4 (13.2 to 31.7)
Swelling: Moderate10.2 (3.4 to 22.2)24.2 (16.0 to 34.1)7.0 (1.5 to 19.1)4.1 (0.9 to 11.5)
Swelling: Severe0.0 (0.0 to 7.5)7.3 (2.7 to 15.2)2.4 (0.1 to 12.6)1.4 (0.0 to 7.4)
Pain: Any78.5 (67.8 to 86.9)84.8 (78.3 to 89.9)83.9 (74.5 to 90.9)93.1 (88.2 to 96.4)
Pain: Mild76.3 (65.2 to 85.3)80.1 (73.0 to 86.1)81.9 (72.0 to 89.5)90.9 (85.4 to 94.8)
Pain: Moderate24.5 (13.8 to 38.3)51.4 (41.7 to 61.0)44.1 (31.2 to 57.6)53.6 (43.9 to 63.0)
Pain: Severe2.1 (0.1 to 11.1)11.6 (5.7 to 20.3)9.1 (2.5 to 21.7)5.3 (1.5 to 13.1)
Limitation of arm movement: Any27.8 (16.5 to 41.6)48.2 (38.7 to 57.9)42.1 (29.1 to 55.9)51.4 (41.6 to 61.1)
Limitation of arm movement: Mild24.1 (13.5 to 37.6)46.4 (36.8 to 56.1)40.4 (27.6 to 54.2)48.1 (38.3 to 58.0)
Limitation of arm movement:Moderate4.3 (0.5 to 14.5)3.7 (0.8 to 10.4)7.0 (1.5 to 19.1)9.1 (3.7 to 17.8)
Limitation of arm movement: Severe2.1 (0.1 to 11.3)9.5 (4.2 to 17.9)4.9 (0.6 to 16.5)5.2 (1.4 to 12.8)
Other pre-specifiedPercentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination 2 (Year 3 to 4) in Cohort 1 and Cohort 2

Systemic events reported using an electronic diary. Systemic events are any fever \>=38 degrees C, fatigue, headache, chills, rash, vomiting, decreased appetite, new generalized muscle pain, aggravated generalized muscle pain , new generalized joint pain), and aggravated generalized joint pain.

Time frame:
Within 14 days after vaccination 2
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination 2 (Year 3 to 4) in Cohort 1 and Cohort 2
Percentage of participants13vPnC/13vPnC, Cohort 123vPS/23vPS, Cohort 113vPnC/23vPS, Cohort 113vPnC/13vPnC, Cohort 2
Fever >=38 degrees C2.1 (0.1 to 11.1)2.5 (0.3 to 8.8)4.7 (0.6 to 15.8)2.7 (0.3 to 9.3)
Fever >= 38 to <38.5 degrees C0.0 (0.0 to 7.5)2.5 (0.3 to 8.8)2.4 (0.1 to 12.6)2.7 (0.3 to 9.3)
Fever >=38.5 to <39 degrees C2.1 (0.1 to 11.1)0.0 (0.0 to 4.6)2.4 (0.1 to 12.6)0.0 (0.0 to 4.9)
Fever >=39 to =<40 degrees C0.0 (0.0 to 7.5)0.0 (0.0 to 4.6)0.0 (0.0 to 8.6)0.0 (0.0 to 4.9)
Fever >40 degrees C0.0 (0.0 to 7.5)0.0 (0.0 to 4.6)0.0 (0.0 to 8.6)0.0 (0.0 to 4.9)
Fatigue50.7 (38.4 to 63.03)57.6 (48.4 to 66.4)63.2 (50.7 to 74.6)60.8 (51.7 to 69.4)
Headache38.3 (26.1 to 51.8)54.2 (44.8 to 63.4)50.0 (37.2 to 62.8)61.8 (52.6 to 70.4)
Chills23.1 (12.5 to 36.8)34.3 (25.1 to 44.6)33.9 (21.8 to 47.8)25.8 (17.3 to 35.9)
Rash23.5 (12.8 to 37.5)32.6 (23.4 to 43.0)18.4 (8.8 to 32.0)13.6 (7.0 to 23.0)
Vomiting8.3 (2.3 to 20.0)1.3 (0.0 to 6.9)4.7 (0.6 to 15.8)3.9 (0.8 to 11.1)
Decreased appetite21.2 (11.1 to 34.7)23.7 (15.5 to 33.6)31.5 (19.5 to 45.6)24.7 (16.2 to 35.0)
New generalized muscle pain55.0 (41.6 to 67.9)67.6 (59.1 to 75.4)65.2 (52.4 to 76.5)69.5 (60.8 to 77.4)
Aggravated generalized muscle pain27.5 (15.9 to 41.7)39.6 (30.0 to 49.8)41.4 (28.6 to 55.1)34.7 (25.3 to 45.2)
New generalized joint pain18.9 (9.4 to 32.0)23.1 (14.9 to 33.1)24.5 (13.8 to 38.3)33.3 (23.9 to 43.9)
Aggravated generalized joint pain13.7 (5.7 to 26.3)17.6 (10.4 to 27.0)22.4 (11.8 to 36.6)25.0 (16.4 to 35.4)
PrimarySerotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) 1 Month After Vaccination 1

Serotype-specific OPA GMTs for the 13 pneumococcal common serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of all the participants using microcolony OPA (mcOPA) assay. CIs for GMT are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.

Time frame:
One month after vaccination 1
Reported as:
Geometric mean · titer
Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) 1 Month After Vaccination 1
titer13vPnC, Cohort 123vPS, Cohort 113vPnC, Cohort 213vPnC, Cohort 3
1146 (124.0 to 172.9)104 (87.7 to 124.4)200 (170.3 to 236.0)353 (322.8 to 386.9)
393 (81.1 to 106.6)85 (74.2 to 98.3)91 (79.9 to 104.7)91 (84.2 to 98.4)
42062 (1693.6 to 2510.5)1295 (1045.9 to 1603.0)2833 (2412.1 to 3327.4)4747 (4370.2 to 5155.5)
5199 (164.0 to 242.3)162 (133.6 to 197.5)269 (218.1 to 332.5)386 (342.6 to 435.8)
6A2593 (2146.7 to 3131.1)213 (160.3 to 284.3)4328 (3658.1 to 5121.5)5746 (5240.7 to 6300.4)
6B1984 (1604.0 to 2453.6)788 (615.9 to 1008.5)3212 (2728.6 to 3781.4)9813 (9097.8 to 10583.5)
7F1120 (907.6 to 1382.9)405 (311.9 to 524.7)1520 (1274.5 to 1812.1)3249 (2994.8 to 3523.9)
9V1164 (934.8 to 1448.3)407 (307.2 to 539.8)1726 (1428.5 to 2086.2)3339 (3037.4 to 3670.4)
14612 (489.6 to 764.2)692 (553.3 to 866.2)957 (779.6 to 1174.5)2983 (2740.5 to 3246.6)
18C1726 (1429.7 to 2082.9)925 (735.3 to 1162.9)1939 (1599.2 to 2350.2)3989 (3629.4 to 4383.8)
19A682 (596.5 to 779.9)352 (297.0 to 416.1)956 (837.6 to 1090.7)1580 (1471.4 to 1696.3)
19F517 (420.8 to 635.3)539 (442.1 to 658.2)599 (491.0 to 731.0)1533 (1397.3 to 1680.9)
23F375 (297.2 to 472.6)72 (55.9 to 93.4)494 (386.8 to 630.7)1570 (1392.8 to 1770.2)
Statistical analysis
  • 13vPnC, Cohort 1 vs 23vPS, Cohort 1 · Gmt ratio: 1.4 · 95% CI 1.10 to 1.78
  • 13vPnC, Cohort 1 vs 23vPS, Cohort 1 · Gmt ratio: 1.1 · 95% CI 0.90 to 1.32
  • 13vPnC, Cohort 1 vs 23vPS, Cohort 1 · Gmt ratio: 1.6 · 95% CI 1.19 to 2.13
  • 13vPnC, Cohort 1 vs 23vPS, Cohort 1 · Gmt ratio: 1.2 · 95% CI 0.93 to 1.62
  • 13vPnC, Cohort 1 vs 23vPS, Cohort 1 · Gmt ratio: 12.1 · 95% CI 8.63 to 17.08
  • 13vPnC, Cohort 1 vs 23vPS, Cohort 1 · Gmt ratio: 2.5 · 95% CI 1.82 to 3.48
  • 13vPnC, Cohort 1 vs 23vPS, Cohort 1 · Gmt ratio: 2.8 · 95% CI 1.98 to 3.87
  • 13vPnC, Cohort 1 vs 23vPS, Cohort 1 · Gmt ratio: 2.9 · 95% CI 2.00 to 4.08
  • 13vPnC, Cohort 1 vs 23vPS, Cohort 1 · Gmt ratio: 0.9 · 95% CI 0.64 to 1.21
  • 13vPnC, Cohort 1 vs 23vPS, Cohort 1 · Gmt ratio: 1.9 · 95% CI 1.39 to 2.51
  • 13vPnC, Cohort 1 vs 23vPS, Cohort 1 · Gmt ratio: 1.9 · 95% CI 1.56 to 2.41
  • 13vPnC, Cohort 1 vs 23vPS, Cohort 1 · Gmt ratio: 1.0 · 95% CI 0.72 to 1.28
  • 13vPnC, Cohort 1 vs 23vPS, Cohort 1 · Gmt ratio: 5.2 · 95% CI 3.67 to 7.33
  • 13vPnC, Cohort 1 vs 13vPnC, Cohort 2 · Gmt ratio: 1.4 · 95% CI 1.08 to 1.73
  • 13vPnC, Cohort 1 vs 13vPnC, Cohort 2 · Gmt ratio: 1.0 · 95% CI 0.81 to 1.19
  • 13vPnC, Cohort 1 vs 13vPnC, Cohort 2 · Gmt ratio: 1.4 · 95% CI 1.07 to 1.77
  • 13vPnC, Cohort 1 vs 13vPnC, Cohort 2 · Gmt ratio: 1.4 · 95% CI 1.01 to 1.80
  • 13vPnC, Cohort 1 vs 13vPnC, Cohort 2 · Gmt ratio: 1.7 · 95% CI 1.30 to 2.15
  • 13vPnC, Cohort 1 vs 13vPnC, Cohort 2 · Gmt ratio: 1.6 · 95% CI 1.24 to 2.12
  • 13vPnC, Cohort 1 vs 13vPnC, Cohort 2 · Gmt ratio: 1.4 · 95% CI 1.03 to 1.79
  • 13vPnC, Cohort 1 vs 13vPnC, Cohort 2 · Gmt ratio: 1.5 · 95% CI 1.11 to 1.98
  • 13vPnC, Cohort 1 vs 13vPnC, Cohort 2 · Gmt ratio: 1.6 · 95% CI 1.16 to 2.12
  • 13vPnC, Cohort 1 vs 13vPnC, Cohort 2 · Gmt ratio: 1.1 · 95% CI 0.86 to 1.47
  • 13vPnC, Cohort 1 vs 13vPnC, Cohort 2 · Gmt ratio: 1.4 · 95% CI 1.16 to 1.69
  • 13vPnC, Cohort 1 vs 13vPnC, Cohort 2 · Gmt ratio: 1.2 · 95% CI 0.87 to 1.54
  • 13vPnC, Cohort 1 vs 13vPnC, Cohort 2 · Gmt ratio: 1.3 · 95% CI 0.94 to 1.84
  • 13vPnC, Cohort 1 vs 13vPnC, Cohort 3 · Gmt ratio: 2.4 · 95% CI 2.03 to 2.87
  • 13vPnC, Cohort 1 vs 13vPnC, Cohort 3 · Gmt ratio: 1.0 · 95% CI 0.84 to 1.13
  • 13vPnC, Cohort 1 vs 13vPnC, Cohort 3 · Gmt ratio: 2.3 · 95% CI 1.92 to 2.76
  • 13vPnC, Cohort 1 vs 13vPnC, Cohort 3 · Gmt ratio: 1.9 · 95% CI 1.55 to 2.42
  • 13vPnC, Cohort 1 vs 13vPnC, Cohort 3 · Gmt ratio: 2.2 · 95% CI 1.84 to 2.67
  • 13vPnC, Cohort 1 vs 13vPnC, Cohort 3 · Gmt ratio: 4.9 · 95% CI 4.13 to 5.93
  • 13vPnC, Cohort 1 vs 13vPnC, Cohort 3 · Gmt ratio: 2.9 · 95% CI 2.41 to 3.49
  • 13vPnC, Cohort 1 vs 13vPnC, Cohort 3 · Gmt ratio: 2.9 · 95% CI 2.34 to 3.52
  • 13vPnC, Cohort 1 vs 13vPnC, Cohort 3 · Gmt ratio: 4.9 · 95% CI 4.01 to 5.93
  • 13vPnC, Cohort 1 vs 13vPnC, Cohort 3 · Gmt ratio: 2.3 · 95% CI 1.91 to 2.79
  • 13vPnC, Cohort 1 vs 13vPnC, Cohort 3 · Gmt ratio: 2.3 · 95% CI 2.02 to 2.66
  • 13vPnC, Cohort 1 vs 13vPnC, Cohort 3 · Gmt ratio: 3.0 · 95% CI 2.44 to 3.60
  • 13vPnC, Cohort 1 vs 13vPnC, Cohort 3 · Gmt ratio: 4.2 · 95% CI 3.31 to 5.31
PrimaryPercentage of Participants Achieving At Least a 4-fold Rise in OPA Titer for Serotype 6A 1 Month After Vaccination 1 in Cohort 1

For serotype 6A the percentage of participants achieving at least a 4-fold rise on the serotype-specific antibody titer from pre-vaccination to 1 month post-vaccination was computed along with exact, 2-sided 95% confidence interval for the proportion.

Time frame:
One month after vaccination 1
Reported as:
Number · percentage of participants
Percentage of Participants Achieving At Least a 4-fold Rise in OPA Titer for Serotype 6A 1 Month After Vaccination 1 in Cohort 1
percentage of participants13vPnC, Cohort 123vPS, Cohort 1
Percentage of Participants Achieving At Least a 4-fold Rise in OPA Titer for Serotype 6A 1 Month After Vaccination 1 in Cohort 188.5 (84.8 to 91.6)49.3 (44.2 to 54.5)
Statistical analysis
  • 13vPnC, Cohort 1 vs 23vPS, Cohort 1 · Difference in percentage: 39.2 · 95% CI 33.0 to 45.1
PrimarySerotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) 1 Month After Vaccination for 12 Common Serotypes in 13vPnC/23vPS Group Relative to 23vPS Group and 23vPS/23vPS Group

Serotype-specific OPA GMTs for the 12 pneumococcal common serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of all the participants using mcOPA assay. CIs for GMT are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.

Time frame:
One month after vaccination 1 and One month after vaccination 2/Year 3 to 4
Reported as:
Geometric mean · titers
Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) 1 Month After Vaccination for 12 Common Serotypes in 13vPnC/23vPS Group Relative to 23vPS Group and 23vPS/23vPS Group
titers13vPnC/23vPS, Cohort 123vPS, Cohort 123vPs/23vPS, Cohort 1
1398 (306.2 to 516.3)116 (89.4 to 149.6)95 (74.8 to 121.1)
3164 (129.0 to 207.5)105 (85.3 to 128.7)53 (42.8 to 64.4)
41875 (1488.8 to 2360.7)1420 (1066.2 to 1890.5)733 (555.1 to 968.2)
5476 (356.2 to 636.1)149 (111.1 to 201.2)74 (54.2 to 100.3)
6B2670 (2012.9 to 3540.6)1088 (774.7 to 1528.1)916 (670.0 to 1252.4)
7F1895 (1471.0 to 2441.1)403 (276.3 to 588.9)497 (361.8 to 682.0)
9V1089 (699.2 to 1695.0)654 (452.5 to 944.9)187 (125.0 to 280.3)
141268 (951.8 to 1690.0)824 (612.9 to 1107.8)661 (515.6 to 848.6)
18C2489 (1941.1 to 3192.7)1135 (815.7 to 1578.6)802 (597.5 to 1076.8)
19A966 (763.2 to 1223.6)377 (296.1 to 479.6)364 (290.0 to 458.0)
19F1653 (1302.2 to 2099.5)621 (468.6 to 821.7)374 (286.1 to 488.2)
23F299 (203.9 to 437.5)86 (58.8 to 124.5)54 (38.4 to 77.0)
Statistical analysis
  • 13vPnC/23vPS, Cohort 1 vs 23vPS, Cohort 1 · Gmt ratio: 3.4 · 95% CI 2.32 to 5.09
  • 13vPnC/23vPS, Cohort 1 vs 23vPS, Cohort 1 · Gmt ratio: 1.6 · 95% CI 1.13 to 2.16
  • 13vPnC/23vPS, Cohort 1 vs 23vPS, Cohort 1 · Gmt ratio: 1.3 · 95% CI 0.88 to 1.98
  • 13vPnC/23vPS, Cohort 1 vs 23vPS, Cohort 1 · Gmt ratio: 3.2 · 95% CI 2.04 to 4.97
  • 13vPnC/23vPS, Cohort 1 vs 23vPS, Cohort 1 · Gmt ratio: 2.5 · 95% CI 1.50 to 4.00
  • 13vPnC/23vPS, Cohort 1 vs 23vPS, Cohort 1 · Gmt ratio: 4.7 · 95% CI 2.76 to 7.99
  • 13vPnC/23vPS, Cohort 1 vs 23vPS, Cohort 1 · Gmt ratio: 1.7 · 95% CI 0.93 to 2.97
  • 13vPnC/23vPS, Cohort 1 vs 23vPS, Cohort 1 · Gmt ratio: 1.5 · 95% CI 0.99 to 2.39
  • 13vPnC/23vPS, Cohort 1 vs 23vPS, Cohort 1 · Gmt ratio: 2.2 · 95% CI 1.37 to 3.50
  • 13vPnC/23vPS, Cohort 1 vs 23vPS, Cohort 1 · Gmt ratio: 2.6 · 95% CI 1.78 to 3.68
  • 13vPnC/23vPS, Cohort 1 vs 23vPS, Cohort 1 · Gmt ratio: 2.7 · 95% CI 1.77 to 4.01
  • 13vPnC/23vPS, Cohort 1 vs 23vPS, Cohort 1 · Gmt ratio: 3.5 · 95% CI 1.99 to 6.13
  • 13vPnC/23vPS, Cohort 1 vs 23vPs/23vPS, Cohort 1 · Gmt ratio: 4.2 · 95% CI 2.87 to 6.08
  • 13vPnC/23vPS, Cohort 1 vs 23vPs/23vPS, Cohort 1 · Gmt ratio: 3.1 · 95% CI 2.26 to 4.30
  • 13vPnC/23vPS, Cohort 1 vs 23vPs/23vPS, Cohort 1 · Gmt ratio: 2.6 · 95% CI 1.72 to 3.80
  • 13vPnC/23vPS, Cohort 1 vs 23vPs/23vPS, Cohort 1 · Gmt ratio: 6.5 · 95% CI 4.09 to 10.19
  • 13vPnC/23vPS, Cohort 1 vs 23vPs/23vPS, Cohort 1 · Gmt ratio: 2.9 · 95% CI 1.83 to 4.63
  • 13vPnC/23vPS, Cohort 1 vs 23vPs/23vPS, Cohort 1 · Gmt ratio: 3.8 · 95% CI 2.41 to 6.03
  • 13vPnC/23vPS, Cohort 1 vs 23vPs/23vPS, Cohort 1 · Gmt ratio: 5.8 · 95% CI 3.13 to 10.82
  • 13vPnC/23vPS, Cohort 1 vs 23vPs/23vPS, Cohort 1 · Gmt ratio: 1.9 · 95% CI 1.30 to 2.84
  • 13vPnC/23vPS, Cohort 1 vs 23vPs/23vPS, Cohort 1 · Gmt ratio: 3.1 · 95% CI 2.02 to 4.78
  • 13vPnC/23vPS, Cohort 1 vs 23vPs/23vPS, Cohort 1 · Gmt ratio: 2.7 · 95% CI 1.87 to 3.76
  • 13vPnC/23vPS, Cohort 1 vs 23vPs/23vPS, Cohort 1 · Gmt ratio: 4.4 · 95% CI 2.97 to 6.58
  • 13vPnC/23vPS, Cohort 1 vs 23vPs/23vPS, Cohort 1 · Gmt ratio: 5.5 · 95% CI 3.20 to 9.41
SecondaryPercentage of Participants Achieving OPA Titers With at Least Lower Limit of Quantification (LLOQ) 1 Month After Vaccination 1

Percentage of participants achieving OPA GMTs with at least LLOQ for 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) determined in blood samples of all participants using mcOPA assay. Exact 2-sided CI based on observed proportion of participants. LLOQ for each serotype: 1=1:18, 3=1:12, 4=1:21, 5=1:29, 6A=1:37, 6B=1:43, 7F=1:210, 9V=1:345, 14=1:35, 18C=1:31, 19A=1:18, 19F=1:48, 23F=1:13.

Time frame:
One month after vaccination 1
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving OPA Titers With at Least Lower Limit of Quantification (LLOQ) 1 Month After Vaccination 1
Percentage of participants13vPnC, Cohort 123vPS, Cohort 113vPnC, Cohort 213vPnC, Cohort 3
190.3 (87.0 to 93.0)83.8 (79.9 to 87.3)94.0 (91.1 to 96.1)97.6 (96.3 to 98.5)
392.1 (89.0 to 94.6)88.3 (84.7 to 91.3)92.3 (89.2 to 94.8)94.8 (93.1 to 96.2)
495.0 (92.2 to 97.0)91.6 (88.2 to 94.2)97.4 (95.2 to 98.8)99.2 (98.3 to 99.7)
587.0 (83.3 to 90.2)84.7 (80.8 to 88.1)86.1 (82.1 to 89.4)92.1 (90.1 to 93.8)
6A95.8 (93.3 to 97.5)69.1 (64.3 to 73.7)97.9 (95.9 to 99.1)99.4 (98.6 to 99.8)
6B93.5 (90.5 to 95.8)86.0 (82.0 to 89.4)97.5 (95.3 to 98.9)99.9 (99.4 to 100.0)
7F90.4 (87.0 to 93.1)78.0 (73.6 to 82.0)94.7 (91.9 to 96.7)98.6 (97.6 to 99.3)
9V89.9 (86.4 to 92.8)75.8 (71.1 to 80.1)93.7 (90.7 to 96.0)97.7 (96.5 to 98.6)
1487.7 (84.0 to 90.9)88.6 (85.0 to 91.6)92.0 (88.7 to 94.5)99.0 (98.0 to 99.5)
18C95.5 (92.9 to 97.4)89.0 (85.4 to 91.9)94.9 (92.2 to 96.9)98.6 (97.5 to 99.3)
19A98.5 (96.7 to 99.4)94.3 (91.5 to 96.4)98.4 (96.6 to 99.4)99.9 (99.4 to 100.0)
19F89.7 (86.1 to 92.5)90.8 (87.4 to 93.6)91.6 (88.2 to 94.2)98.1 (96.9 to 98.9)
23F84.5 (80.5 to 88.0)61.3 (56.2 to 66.3)85.1 (81.0 to 88.5)95.1 (93.4 to 96.4)
Statistical analysis
  • 13vPnC, Cohort 1 vs 23vPS, Cohort 1 · Difference in percentage: 6.5 · 95% CI 1.9 to 11.2
  • 13vPnC, Cohort 1 vs 23vPS, Cohort 1 · Difference in percentage: 3.9 · 95% CI -0.3 to 8.1
  • 13vPnC, Cohort 1 vs 23vPS, Cohort 1 · Difference in percentage: 3.4 · 95% CI -0.2 to 7.2
  • 13vPnC, Cohort 1 vs 23vPS, Cohort 1 · Difference in percentage: 2.3 · 95% CI -2.6 to 7.2
  • 13vPnC, Cohort 1 vs 23vPS, Cohort 1 · Difference in percentage: 26.6 · 95% CI 21.7 to 31.7
  • 13vPnC, Cohort 1 vs 23vPS, Cohort 1 · Difference in percentage: 7.5 · 95% CI 3.2 to 12.0
  • 13vPnC, Cohort 1 vs 23vPS, Cohort 1 · Difference in percentage: 12.3 · 95% CI 7.3 to 17.4
  • 13vPnC, Cohort 1 vs 23vPS, Cohort 1 · Difference in percentage: 14.1 · 95% CI 8.7 to 19.5
  • 13vPnC, Cohort 1 vs 23vPS, Cohort 1 · Difference in percentage: -0.9 · 95% CI -5.6 to 3.8
  • 13vPnC, Cohort 1 vs 23vPS, Cohort 1 · Difference in percentage: 6.5 · 95% CI 2.6 to 10.5
  • 13vPnC, Cohort 1 vs 23vPS, Cohort 1 · Difference in percentage: 4.1 · 95% CI 1.2 to 7.1
  • 13vPnC, Cohort 1 vs 23vPS, Cohort 1 · Difference in percentage: -1.2 · 95% CI -5.5 to 3.2
  • 13vPnC, Cohort 1 vs 23vPS, Cohort 1 · Difference in percentage: 23.2 · 95% CI 17.0 to 29.3
  • 13vPnC, Cohort 1 vs 13vPnC, Cohort 2 · Difference in percentage: 3.6 · 95% CI -0.2 to 7.5
  • 13vPnC, Cohort 1 vs 13vPnC, Cohort 2 · Difference in percentage: 0.2 · 95% CI -3.6 to 4.1
  • 13vPnC, Cohort 1 vs 13vPnC, Cohort 2 · Difference in percentage: 2.4 · 95% CI -0.4 to 5.5
  • 13vPnC, Cohort 1 vs 13vPnC, Cohort 2 · Difference in percentage: -0.9 · 95% CI -5.8 to 3.9
  • 13vPnC, Cohort 1 vs 13vPnC, Cohort 2 · Difference in percentage: 2.2 · 95% CI -0.4 to 4.8
  • 13vPnC, Cohort 1 vs 13vPnC, Cohort 2 · Difference in percentage: 4.0 · 95% CI 0.8 to 7.2
  • 13vPnC, Cohort 1 vs 13vPnC, Cohort 2 · Difference in percentage: 4.4 · 95% CI 0.6 to 8.2
  • 13vPnC, Cohort 1 vs 13vPnC, Cohort 2 · Difference in percentage: 3.8 · 95% CI -0.3 to 7.9
  • 13vPnC, Cohort 1 vs 13vPnC, Cohort 2 · Difference in perecentage: 4.2 · 95% CI -0.1 to 8.7
  • 13vPnC, Cohort 1 vs 13vPnC, Cohort 2 · Difference in percentage: -0.6 · 95% CI -3.8 to 2.5
  • 13vPnC, Cohort 1 vs 13vPnC, Cohort 2 · Difference in percentage: -0.1 · 95% CI -2.1 to 1.9
  • 13vPnC, Cohort 1 vs 13vPnC, Cohort 2 · Difference in percentage: 1.9 · 95% CI -2.4 to 6.2
  • 13vPnC, Cohort 1 vs 13vPnC, Cohort 2 · Difference in percentage: 0.5 · 95% CI -4.7 to 5.7
  • 13vPnC, Cohort 1 vs 13vPnC, Cohort 3 · Difference in percentage: 7.2 · 95% CI 4.3 to 10.6
  • 13vPnC, Cohort 1 vs 13vPnC, Cohort 3 · Difference in percentage: 2.6 · 95% CI -0.3 to 5.9
  • 13vPnC, Cohort 1 vs 13vPnC, Cohort 3 · Difference in percentage: 4.2 · 95% CI 2.1 to 6.9
  • 13vPnC, Cohort 1 vs 13vPnC, Cohort 3 · Difference in percentage: 5.1 · 95% CI 1.4 to 9.1
  • 13vPnC, Cohort 1 vs 13vPnC, Cohort 3 · Difference in percentage: 3.7 · 95% CI 1.7 to 6.1
  • 13vPnC, Cohort 1 vs 13vPnC, Cohort 3 · Difference in percentage: 6.4 · 95% CI 4.1 to 9.3
  • 13vPnC, Cohort 1 vs 13vPnC, Cohort 3 · Difference in percentage: 8.2 · 95% CI 5.4 to 11.6
  • 13vPnC, Cohort 1 vs 13vPnC, Cohort 3 · Difference in percentage: 7.8 · 95% CI 4.8 to 11.4
  • 13vPnC, Cohort 1 vs 13vPnC, Cohort 3 · Difference in percentage: 11.2 · 95% CI 8.0 to 14.9
  • 13vPnC, Cohort 1 vs 13vPnC, Cohort 3 · Difference in percentage: 3.1 · 95% CI 0.9 to 5.7
  • 13vPnC, Cohort 1 vs 13vPnC, Cohort 3 · Difference in percentage: 1.4 · 95% CI 0.3 to 3.1
  • 13vPnC, Cohort 1 vs 13vPnC, Cohort 3 · Difference in percentage: 8.4 · 95% CI 5.4 to 12.0
  • 13vPnC, Cohort 1 vs 13vPnC, Cohort 3 · Difference in percentage: 10.5 · 95% CI 6.8 to 14.7
SecondaryPneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Fold Rises (GMFRs) for the 13 Serotypes From Prevaccination 1 to 1 Month After Vaccination 2 in Cohort 1 and Cohort 2

Geometric mean fold rises (GMFRs) for the 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from prevaccination to 1 month postvaccination were computed using the logarithmically transformed assay results. CI for the GMFRs are back transformations of a CI based on the Student t distribution for the logarithmically transformed assay results.

Time frame:
Prevaccination 1 to 1 month after vaccination 2/Year 3 to 4
Reported as:
Geometric mean · Fold Rise
Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Fold Rises (GMFRs) for the 13 Serotypes From Prevaccination 1 to 1 Month After Vaccination 2 in Cohort 1 and Cohort 2
Fold Rise13vPnC/13vPnC, Cohort 113vPnC/23vPS, Cohort 123vPS/23vPS, Cohort 113vPnC/13vPnC, Cohort 2
172.6 (53.90 to 97.82)69.7 (51.85 to 93.79)15.6 (12.38 to 19.73)54.0 (43.92 to 66.50)
313.2 (9.98 to 17.33)21.2 (15.46 to 29.15)6.8 (5.49 to 8.54)11.5 (9.51 to 13.91)
468.0 (40.04 to 115.58)110.4 (66.47 to 183.22)43.8 (27.87 to 68.74)104.2 (70.96 to 152.94)
547.9 (33.51 to 68.52)83.2 (60.56 to 114.26)11.9 (8.94 to 15.71)52.8 (41.81 to 66.71)
6A142.0 (84.10 to 239.68)116.2 (71.19 to 189.69)6.4 (4.25 to 9.53)139.7 (93.99 to 207.79)
6B103.3 (57.72 to 184.69)63.6 (34.73 to 116.29)24.9 (15.98 to 38.77)132.7 (84.86 to 207.38)
7F140.8 (91.49 to 216.59)293.9 (203.35 to 424.67)72.1 (50.27 to 103.53)218.0 (169.33 to 280.62)
9V24.7 (12.86 to 47.32)40.1 (21.13 to 76.11)10.6 (6.52 to 17.13)49.9 (32.88 to 75.68)
1420.6 (12.31 to 34.57)36.6 (22.02 to 60.97)19.9 (13.85 to 28.67)26.6 (18.43 to 38.52)
18C67.9 (41.02 to 112.48)80.9 (48.89 to 133.79)27.5 (19.10 to 39.69)94.9 (67.89 to 132.54)
19A37.6 (25.57 to 55.37)43.1 (29.21 to 63.51)15.4 (11.79 to 20.25)30.9 (23.56 to 40.43)
19F54.1 (34.08 to 86.01)110.3 (71.30 to 170.65)25.1 (18.04 to 34.84)60.4 (43.40 to 84.06)
23F115.7 (77.40 to 172.81)32.5 (21.38 to 49.40)6.4 (4.57 to 8.85)130.0 (94.64 to 178.44)
SecondarySerotype-specific Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentration (GMC) for 12 Common Serotypes in 13vPnC/23vPS Group Relative to 23vPS and 23vPS/23vPS Groups in Cohort 1; and in 13vPnC/13vPnC Group in Cohort 2, 1 Month After Vaccination

Antibody geometric mean concentration (GMC) as measured by microgram/milliliter (mcg/mL) for 12 common pneumococcal serotypes (1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) are presented. GMC and corresponding 2-sided 95% confidence intervals (CI) were evaluated. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw.

Time frame:
One month after vaccination 1 and One month after vaccination 2/Year 3 to 4
Reported as:
Geometric mean · mcg/mL
Serotype-specific Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentration (GMC) for 12 Common Serotypes in 13vPnC/23vPS Group Relative to 23vPS and 23vPS/23vPS Groups in Cohort 1; and in 13vPnC/13vPnC Group in Cohort 2, 1 Month After Vaccination
mcg/mL13vPnC/23vPS, Cohort 123vPS, Cohort 123vPs/23vPS, Cohort 113vPnC/13vPnC, Cohort 2
19.53 (7.53 to 12.07)4.13 (2.86 to 5.96)4.36 (3.33 to 5.72)6.92 (5.31 to 9.03)
32.58 (2.14 to 3.11)1.88 (1.29 to 2.74)1.81 (1.44 to 2.29)1.33 (1.07 to 1.64)
43.68 (2.86 to 4.74)1.59 (1.06 to 2.37)1.49 (1.14 to 1.95)4.89 (3.83 to 6.25)
511.52 (9.09 to 14.61)8.23 (5.81 to 11.67)5.78 (4.66 to 7.16)7.23 (5.67 to 9.22)
6B11.50 (9.21 to 14.37)7.81 (5.74 to 10.61)5.65 (4.58 to 6.97)19.07 (14.59 to 24.92)
7F8.52 (6.83 to 10.62)8.24 (5.38 to 12.60)4.61 (3.57 to 5.95)6.26 (5.19 to 7.54)
9V7.39 (5.99 to 9.10)5.50 (4.15 to 7.30)3.78 (3.07 to 4.65)4.97 (4.08 to 6.05)
1416.07 (12.31 to 20.98)12.05 (7.26 to 19.99)8.22 (6.11 to 11.05)14.66 (11.97 to 17.96)
18C8.56 (6.77 to 10.84)8.21 (5.64 to 11.96)6.30 (4.70 to 8.45)7.17 (5.68 to 9.03)
19A14.63 (11.87 to 18.04)12.70 (9.29 to 17.37)9.88 (7.80 to 12.52)16.33 (13.31 to 20.04)
19F11.51 (8.64 to 15.34)6.42 (4.11 to 10.01)3.44 (2.50 to 4.73)12.89 (9.75 to 17.06)
23F7.11 (5.50 to 9.19)4.89 (3.52 to 6.81)3.56 (2.81 to 4.52)17.20 (13.28 to 22.29)
Statistical analysis
  • 13vPnC/23vPS, Cohort 1 vs 23vPS, Cohort 1 · Gmc ratio: 2.31 · 95% CI 1.52 to 3.51
  • 13vPnC/23vPS, Cohort 1 vs 23vPS, Cohort 1 · Gmc ratio: 1.37 · 95% CI 0.95 to 1.99
  • 13vPnC/23vPS, Cohort 1 vs 23vPS, Cohort 1 · Gmc ratio: 2.32 · 95% CI 1.47 to 3.64
  • 13vPnC/23vPS, Cohort 1 vs 23vPS, Cohort 1 · Gmc ratio: 1.40 · 95% CI 0.92 to 2.12
  • 13vPnC/23vPS, Cohort 1 vs 23vPS, Cohort 1 · Gmc ratio: 1.47 · 95% CI 1.01 to 2.16
  • 13vPnC/23vPS, Cohort 1 vs 23vPS, Cohort 1 · Gmc ratio: 1.03 · 95% CI 0.67 to 1.59
  • 13vPnC/23vPS, Cohort 1 vs 23vPS, Cohort 1 · Gmc ratio: 1.34 · 95% CI 0.94 to 1.92
  • 13vPnC/23vPS, Cohort 1 vs 23vPS, Cohort 1 · Gmc ratio: 1.33 · 95% CI 0.80 to 2.23
  • 13vPnC/23vPS, Cohort 1 vs 23vPS, Cohort 1 · Gmc ratio: 1.04 · 95% CI 0.68 to 1.59
  • 13vPnC/23vPS, Cohort 1 vs 23vPS, Cohort 1 · Gmc ratio: 1.15 · 95% CI 0.80 to 1.66
  • 13vPnC/23vPS, Cohort 1 vs 23vPS, Cohort 1 · Gmc ratio: 1.79 · 95% CI 1.07 to 3.00
  • 13vPnC/23vPS, Cohort 1 vs 23vPS, Cohort 1 · Gmc ratio: 1.45 · 95% CI 0.95 to 2.24
  • 13vPnC/23vPS, Cohort 1 vs 23vPs/23vPS, Cohort 1 · Gmc ratio: 2.18 · 95% CI 1.53 to 3.12
  • 13vPnC/23vPS, Cohort 1 vs 23vPs/23vPS, Cohort 1 · Gmc ratio: 1.42 · 95% CI 1.06 to 1.91
  • 13vPnC/23vPS, Cohort 1 vs 23vPs/23vPS, Cohort 1 · Gmc ratio: 2.47 · 95% CI 1.71 to 3.55
  • 13vPnC/23vPS, Cohort 1 vs 23vPs/23vPS, Cohort 1 · Gmc ratio: 1.99 · 95% CI 1.45 to 2.74
  • 13vPnC/23vPS, Cohort 1 vs 23vPs/23vPS, Cohort 1 · Gmc ratio: 2.04 · 95% CI 1.50 to 2.76
  • 13vPnC/23vPS, Cohort 1 vs 23vPs/23vPS, Cohort 1 · Gmc ratio: 1.85 · 95% CI 1.32 to 2.58
  • 13vPnC/23vPS, Cohort 1 vs 23vPs/23vPS, Cohort 1 · Gmc ratio: 1.96 · 95% CI 1.46 to 2.62
  • 13vPnC/23vPS, Cohort 1 vs 23vPs/23vPS, Cohort 1 · Gmc ratio: 1.96 · 95% CI 1.32 to 2.91
  • 13vPnC/23vPS, Cohort 1 vs 23vPs/23vPS, Cohort 1 · Gmc ratio: 1.36 · 95% CI 0.94 to 1.97
  • 13vPnC/23vPS, Cohort 1 vs 23vPs/23vPS, Cohort 1 · Gmc ratio: 1.48 · 95% CI 1.08 to 2.03
  • 13vPnC/23vPS, Cohort 1 vs 23vPs/23vPS, Cohort 1 · Gmc ratio: 3.35 · 95% CI 2.19 to 5.12
  • 13vPnC/23vPS, Cohort 1 vs 23vPs/23vPS, Cohort 1 · Gmc ratio: 2.00 · 95% CI 1.41 to 2.83
Other pre-specifiedPercentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination 1

Local reactions reported using an electronic diary. Redness and Swelling scaled as Any (redness present or swelling present); Mild (2.5 to 5.0 centimeters \[cm\]; Moderate (5.1 to 10.0 cm); Severe (\>10 cm). Pain scaled as Any (pain present); Mild (awareness of pain; easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating); Limitation of arm movement scaled as Any (limitation \[lim\] present); Mild (some limitation); Moderate (unable to move arm above head; able to move arm above shoulder); Severe (unable to move arm above shoulder).

Time frame:
Within 14 days after vaccination 1
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination 1
Percentage of participants13vPnC, Cohort 123vPS, Cohort 113vPnC, Cohort 213vPnC, Cohort 3
Redness: Any20.2 (14.8 to 26.6)14.2 (9.6 to 20.0)15.8 (10.4 to 22.6)30.5 (25.0 to 36.4)
Redness: Mild15.9 (11.0 to 21.9)11.2 (7.1 to 16.7)15.2 (9.9 to 22.0)26.4 (21.1 to 32.2)
Redness: Moderate8.6 (5.0 to 13.7)4.9 (2.3 to 9.2)5.0 (2.0 to 10.0)11.9 (8.0 to 16.8)
Redness: Severe1.7 (0.3 to 4.8)0.0 (0.0 to 0.2)0.7 (0.0 to 4.0)2.8 (1.1 to 6.1)
Swelling: Any19.3 (14.0 to 25.5)13.1 (8.7 to 18.7)21.7 (15.6 to 28.9)39.4 (33.9 to 45.2)
Swelling: Mild15.6 (10.8 to 21.5)10.1 (6.2 to 15.3)20.6 (14.6 to 27.7)37.2 (31.7 to 43.0)
Swelling: Moderate8.2 (4.6 to 13.1)4.4 (1.9 to 8.5)4.3 (1.6 to 9.2)15.1 (10.8 to 20.3)
Swelling: Severe0.6 (0.0 to 3.1)1.1 (0.1 to 4.0)0.0 (0.0 to 2.7)1.4 (0.3 to 4.1)
Pain: Any80.1 (75.3 to 84.2)73.4 (68.1 to 78.3)88.8 (84.9 to 92.0)96.7 (95.2 to 97.8)
Pain: Mild78.6 (73.8 to 83.0)68.6 (62.9 to 73.9)85.9 (81.5 to 89.6)93.2 (91.1 to 94.4)
Pain: Moderate23.3 (17.7 to 29.7)30.0 (23.9 to 36.7)39.5 (32.5 to 46.8)77.1 (73.0 to 80.8)
Pain: Severe1.7 (0.3 to 4.8)8.6 (5.0 to 13.5)3.6 (1.2 to 8.2)16.0 (11.6 to 21.3)
Lim of arm movement:Any28.5 (22.6 to 35.1)30.8 (24.6 to 37.5)40.7 (33.7 to 48.0)75.2 (71.1 to 78.9)
Lim of arm movement:Mild26.9 (21.0 to 33.4)29.3 (23.2 to 36.0)38.6 (31.6 to 46.0)71.5 (67.1 to 75.5)
Lim of arm movement:Moderate2.2 (0.6 to 5.6)3.8 (1.6 to 7.8)2.9 (0.8 to 7.2)18.5 (13.8 to 24.0)
Lim of arm movement:Severe1.7 (0.3 to 4.8)4.3 (1.9 to 8.3)2.9 (0.8 to 7.2)15.6 (11.2 to 20.9)
Other pre-specifiedPercentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination 1

Systemic events reported using an electronic diary. Systemic events are any fever greater than or equal to (\>=) 38 degrees Celsius \[C\], fatigue, headache, chills, rash, vomiting, decreased appetite, new generalized (gen) muscle pain, aggravated generalized muscle pain , new generalized joint pain), and aggravated generalized joint pain. All reports of fever \>40 degrees C in 13vPnC and 23vPS for Cohort 1 were confirmed as data entry errors.

Time frame:
Within 14 days after vaccination 1
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination 1
Percentage of participants13vPnC, Cohort 123vPS, Cohort 113vPnC, Cohort 213vPnC, Cohort 3
Fever >=38 degrees C7.7 (4.3 to 12.6)5.9 (3.0 to 10.4)1.5 (0.2 to 5.2)7.2 (4.2 to 11.5)
Fever >=38 to <38.5 degrees C3.9 (1.6 to 7.9)1.1 (0.1 to 4.0)1.5 (0.2 to 5.2)4.2 (1.9 to 7.8)
Fever >=38.5 to <39 degrees C0.6 (0.0 to 3.1)0.0 (0.0 to 2.0)0.0 (0.0 to 2.7)1.9 (0.5 to 4.8)
Fever >=39 to =<40 degrees C0.0 (0.0 to 2.1)0.0 (0.0 to 2.0)0.0 (0.0 to 2.7)1.4 (0.3 to 4.1)
Fever >40 degrees C4.4 (1.9 to 8.6)4.9 (2.3 to 9.1)0.0 (0.0 to 2.7)0.5 (0.0 to 2.6)
Fatigue63.2 (57.2 to 68.9)61.5 (55.5 to 67.3)63.3 (57.0 to 69.3)80.5 (77.0 to 83.7)
Headache54.0 (47.6 to 60.2)54.4 (48.2 to 60.6)65.9 (59.6 to 71.8)81.4 (77.8 to 84.6)
Chills23.5 (17.9 to 30.0)24.1 (18.4 to 30.7)19.6 (13.7 to 26.7)38.1 (32.5 to 44.0)
Rash16.5 (11.6 to 22.5)13.0 (8.6 to 18.6)14.2 (9.0 to 20.9)21.3 (16.4 to 26.9)
Vomiting3.9 (1.6 to 7.8)5.4 (2.6 to 9.7)6.9 (3.4 to 12.4)15.0 (10.7 to 20.2)
Decreased appetite21.3 (15.9 to 27.6)21.7 (16.3 to 28.0)25.3 (18.9 to 32.6)55.6 (50.4 to 60.8)
New gen muscle pain56.2 (49.8 to 62.5)57.8 (51.7 to 63.8)61.8 (55.3 to 68.0)82.0 (78.6 to 85.1)
Aggravated gen muscle pain32.6 (26.3 to 39.3)37.3 (31.0 to 44.0)39.9 (32.8 to 47.3)55.9 (50.7 to 61.1)
New gen joint pain24.4 (18.5 to 31.0)30.1 (24.1 to 36.7)31.5 (24.5 to 39.2)41.7 (36.1 to 47.4)
Aggravated gen joint pain24.9 (19.1 to 31.4)21.4 (16.0 to 27.6)25.6 (19.2 to 32.9)28.6 (23.3 to 34.4)

Adverse events

Collected over Adverse events collected after vaccination and at the 6-month follow-up contact. Participants recorded pre-specified AEs in electronic diary: local reactions and systemic events from Day 1-Day 14 post vaccination.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
13vPnC, Cohort 1—1/417 (0.2%)277/417 (66.4%)
13vPnC: 6 Month Follow-up After Vax 1, Cohort 1—12/417 (2.9%)0/417 (0%)
23vPS, Cohort 1—2/414 (0.5%)271/414 (65.5%)
23vPS: 6 Month Follow-up After Vax 1, Cohort 1—10/414 (2.4%)5/414 (1.2%)
13vPnC, Cohort 2—2/403 (0.5%)293/403 (72.7%)
13vPnC: 6 Month Follow-up After Vax 1, Cohort 2—5/403 (1.2%)2/403 (0.5%)
13vPnC/13vPnC, Cohort 1—1/108 (0.9%)66/108 (61.1%)
13vPnC/13vPnC: 6 Month Follow-up After Vax 2, Cohort 1—2/108 (1.9%)1/108 (0.9%)
13vPnC/23vPS, Cohort 1—1/108 (0.9%)73/108 (67.6%)
13vPnC/23vPS: 6 Month Follow-up After Vax 2, Cohort 1—1/108 (0.9%)4/108 (3.7%)
23vPS/23vPS, Cohort 1—0/189 (0%)143/189 (75.7%)
23vPS/23vPS: 6 Month Follow-up After Vax 2, Cohort 1—3/189 (1.6%)13/189 (6.9%)
13vPnC/13vPnC, Cohort 2—0/214 (0%)164/214 (76.6%)
13vPnC/13vPnC: 6 Month Follow-up After Vax 2, Cohort 2—0/214 (0%)4/214 (1.9%)
13vPnC, Cohort 3—2/899 (0.2%)779/899 (86.7%)
13vPnC: 6 Month Follow-up After Vax 1, Cohort 3—2/899 (0.2%)1/899 (0.1%)
Most frequent serious events
Showing 10 of 47
Most frequent serious events
Event13vPnC, Cohort 113vPnC: 6 Month Follow-up After Vax 1, Cohort 123vPS, Cohort 123vPS: 6 Month Follow-up After Vax 1, Cohort 113vPnC, Cohort 213vPnC: 6 Month Follow-up After Vax 1, Cohort 213vPnC/13vPnC, Cohort 113vPnC/13vPnC: 6 Month Follow-up After Vax 2, Cohort 113vPnC/23vPS, Cohort 113vPnC/23vPS: 6 Month Follow-up After Vax 2, Cohort 123vPS/23vPS, Cohort 123vPS/23vPS: 6 Month Follow-up After Vax 2, Cohort 113vPnC/13vPnC, Cohort 213vPnC/13vPnC: 6 Month Follow-up After Vax 2, Cohort 213vPnC, Cohort 313vPnC: 6 Month Follow-up After Vax 1, Cohort 3
Ligament ruptureInjury, poisoning and procedural complications0/4170/4170/4140/4140/4030/4030/1080/1081/1080/1080/1890/1890/2140/2140/8990/899
Erythema multiformeSkin and subcutaneous tissue disorders0/4170/4170/4140/4140/4030/4031/1080/1080/1080/1080/1890/1890/2140/2140/8990/899
Coronary artery diseaseCardiac disorders0/4171/4170/4140/4140/4030/4030/1081/1080/1080/1080/1890/1890/2140/2140/8990/899
PneumoniaInfections and infestations0/4171/4170/4140/4140/4030/4030/1080/1080/1081/1080/1890/1890/2140/2140/8990/899
OsteoarthritisMusculoskeletal and connective tissue disorders0/4171/4170/4140/4140/4030/4030/1081/1080/1080/1080/1890/1890/2140/2140/8990/899
Lumbar vertebral fractureInjury, poisoning and procedural complications0/4170/4170/4140/4140/4030/4030/1080/1080/1080/1080/1891/1890/2140/2140/8990/899
Rib fractureInjury, poisoning and procedural complications0/4170/4170/4140/4140/4030/4030/1080/1080/1080/1080/1891/1890/2140/2140/8990/899
Endometrial cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/4170/4170/4140/4140/4030/4030/1080/1080/1080/1080/1891/1890/2140/2140/8990/899
NystagmusNervous system disorders0/4170/4170/4140/4140/4030/4030/1080/1080/1080/1080/1891/1890/2140/2140/8990/899
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/4171/4170/4142/4140/4030/4030/1080/1080/1080/1080/1890/1890/2140/2140/8990/899
Most frequent other events
Showing 10 of 244
Most frequent other events
Event13vPnC, Cohort 113vPnC: 6 Month Follow-up After Vax 1, Cohort 123vPS, Cohort 123vPS: 6 Month Follow-up After Vax 1, Cohort 113vPnC, Cohort 213vPnC: 6 Month Follow-up After Vax 1, Cohort 213vPnC/13vPnC, Cohort 113vPnC/13vPnC: 6 Month Follow-up After Vax 2, Cohort 113vPnC/23vPS, Cohort 113vPnC/23vPS: 6 Month Follow-up After Vax 2, Cohort 123vPS/23vPS, Cohort 123vPS/23vPS: 6 Month Follow-up After Vax 2, Cohort 113vPnC/13vPnC, Cohort 213vPnC/13vPnC: 6 Month Follow-up After Vax 2, Cohort 213vPnC, Cohort 313vPnC: 6 Month Follow-up After Vax 1, Cohort 3
Pain (Any)Skin and subcutaneous tissue disorders265/331—221/301—286/322—62/79—73/87—139/164—161/173—761/7870/899
Pain (Mild)Skin and subcutaneous tissue disorders254/323—199/290—263/306—58/76—68/83—125/156—150/165—672/7210/899
New generalized muscle painGeneral disorders140/249—155/268—147/238—33/60—43/66—92/136—89/128—460/5610/899
HeadacheGeneral disorders136/252—141/259—162/246—23/60—32/64—64/118—76/123—429/5270/899
FatigueGeneral disorders175/277—168/273—157/248—35/69—43/68—72/125—76/125—446/5540/899
Pain (Moderate)Skin and subcutaneous tissue disorders48/206—63/210—75/190—13/53—26/59—57/111—60/112—360/4670/899
Limitation of arm movement (Any)Skin and subcutaneous tissue disorders61/214—65/211—79/194—15/54—24/57—54/112—56/109—375/4990/899
Limitation of arm movement (Mild)Skin and subcutaneous tissue disorders57/212—61/208—73/189—13/54—23/57—51/110—51/106—333/4660/899
Aggravated generalized muscle painGeneral disorders70/215—84/225—75/188—14/51—24/58—40/101—33/95—207/3700/899
Decreased appetiteGeneral disorders43/202—45/207—42/166—11/52—17/54—22/93—22/89—202/3630/899

Baseline characteristics

Age, Customized
Age, Customized(participants)13vPnC, Cohort 123vPS, Cohort 113vPnC, Cohort 213vPnC, Cohort 3Total
18 to 29 years000300300
30 to 39 years000298298
40 to 49 years000301301
50 to 59 years004030403
60 to 64 years41741400831
Sex: Female, Male
Sex: Female, Male(Participants)13vPnC, Cohort 123vPS, Cohort 113vPnC, Cohort 213vPnC, Cohort 3Total
Female2232522495231247
Male194162154376886
08

Study locations

26 sites
  • Accelovance
    Huntsville, Alabama 35802, United States
  • East Valley Family Physicians, PLC
    Chandler, Arizona 85224, United States
  • Clinical Research Advantage/Central Phoenix
    Phoenix, Arizona 85020, United States
  • University Clinical Research, Inc.
    Pembroke Pines, Florida 33024, United States
  • Advanced Clinical Research
    Meridian, Idaho 83642, United States
  • Accelovance
    South Bend, Indiana 46601, United States
  • Heartland Research Associates LLC
    Wichita, Kansas 67205, United States
  • Heartland Research Associates, LLC
    Wichita, Kansas 67207, United States
  • Kentucky Pediatric /Adult Research
    Bardstown, Kentucky 40004, United States
  • University of Louisville
    Louisville, Kentucky 40202, United States
  • Center for Pharmaceutical Research
    Kansas City, Missouri 64114, United States
  • Radiant Research - St. Louis
    Saint Louis, Missouri 63141, United States
  • University of Rochester Medical Center
    Rochester, New York 14642, United States
  • PMG Research of Raleigh, LLC
    Cary, North Carolina 275188, United States
  • PMG Research of Raleigh, LLC
    Raleigh, North Carolina 27609, United States
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
  • Primary Physicians Research
    Pittsburgh, Pennsylvania 15205, United States
  • Primary Physicians Research
    Upper Saint Clair, Pennsylvania 15241, United States
  • Omega Medical Research
    Warwick, Rhode Island 02886, United States
  • Internal Medicine and Pediatrics Associates of Bristol, PC
    Bristol, Tennessee 37520, United States
  • PMG Research of Bristoll, LLC
    Bristol, Tennessee 37620, United States
  • J. Lewis Research Inc./Foothill Family Clinic South
    Salt Lake City, Utah 84109, United States
  • J. Lewis Research Inc./Foothill Family Clinic South
    Salt Lake City, Utah 84121, United States
  • Advanced Clinical Research
    West Jordan, Utah 84088, United States
  • J. Lewis Research/First Med
    West Jordan, Utah 84088, United States
  • Group Health Research Institute
    Seattle, Washington 98101, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2007 to primary completion in Aug 2011, 53 months.

Results were first posted in Sep 2012, 1 year 1 month after primary completion.

Of 81 industry-sponsored phase 3 interventional studies under Pneumococcal Infections, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 23. This study's 53 months is above that.

Counting every sponsor, half of 82 studies reached it within 13 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2007
First posted
Jan 29, 2007
StartActual
Feb 27, 2007
Primary completionActual
Aug 1, 2011
CompletionActual
Aug 1, 2011
Results first posted
Sep 5, 2012
Last update
Nov 15, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 15, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00427895
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jan 29, 2007
Start date
Feb 27, 2007
Primary completion
Aug 1, 2011
Completion
Aug 1, 2011
Results posted
Sep 5, 2012
Last update
Nov 15, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 13-valent pneumococcal vaccine

Start the discussion